Accumulating evidence indicates that PLOD2 is significantly overexpressed and related to poor prognosis of patients in several types of solid tumors, such as hepatocellular carcinoma [11], pancreatic cancer [12], sarcoma [13], and head and neck squamous cell carcinoma (HNSCC) [14]. Here, PLOD2 is linked to sarcoma.